RT Journal Article
SR Electronic
T1 Prevalence of SARS-CoV-2 and co-occurrence/co-infection with malaria during the first wave of the pandemic (the Burkina Faso case)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.20.22280138
DO 10.1101/2022.09.20.22280138
A1 López-Farfán, Diana
A1 Yerbanga, R. Serge
A1 Parres-Mercader, Marina
A1 Torres-Puente, Manuela
A1 Gómez-Navarro, Inmaculada
A1 Soufiane Sanou, Do Malick
A1 Yao, Adama Franck
A1 Ouédraogo, Jean Bosco
A1 Comas, Iñaki
A1 Irigoyen, Nerea
A1 Gómez-Díaz, Elena
YR 2022
UL http://medrxiv.org/content/early/2022/09/20/2022.09.20.22280138.abstract
AB Africa accounts for 1.5% of the global coronavirus disease 2019 (COVID-19) cases and 2.7% of deaths, but this low incidence has been partly attributed to the limited testing capacity in most countries. In addition, the population in many African countries is at high risk of infection with endemic infectious diseases such as malaria. Our aim is to determine the prevalence and circulation of SARS-CoV-2 variants, and the frequency of co-infection with the malaria parasite. We conducted serological tests and microscopy examinations on 998 volunteers of different ages and sexes in a random and stratified population sample in Burkina-Faso. In addition, nasopharyngeal samples were taken for RT-qPCR of SARS-COV-2 and for whole viral genome sequencing. Our results show a 3.2% and a 2.5% of SARS-CoV-2 seroprevalence and PCR positivity; and 22% of malaria incidence, over the sampling period, with marked differences linked to age. Importantly, we found 2 cases of confirmed co-infection and 8 cases of suspected co-infection mostly in children. Finally, we report the genome sequences of 13 SARS-CoV-2 isolates circulating in Burkina Faso at the time of analysis, assigned to lineages A.19, A.21, B.1.1.404, B.1.1.118, B.1 and grouped into clades; 19B, 20A and 20B. This is the first population-based study about SARS-CoV-2 and malaria in Burkina Faso during the first wave of the pandemic, providing a relevant estimation of the real prevalence of SARS-CoV-2 and variants circulating in this Sub-Saharan African country. Besides, it highlights the low frequency of co-infection with malaria in African communities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research work received funding from by the European Commission NextGenerationEU (Regulation EU 2020/2094) and grant 202020E159 through CSIC Global Health Platform (PTI Salud Global).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This protocol was carried out by the Institut des Sciences et Techniques de Bobo-Dioulasso and was approved by the Spanish National Research Council (CSIC), the Ethics Committee of Biomedical Research in Andalusia (CCEIBA), and the Centre National de la Recherche Scientifique et Technologique (CNRST) of Burkina-Faso. The protocol is in conformity with the declaration of Helsinki and all international regulations about the ethical principles in biomedical research involving human subjects. SARS-CoV-2 seropositive and malaria positive individuals were provided with treatment and assisted by medical professionals. During the screening, local authorities, school directors and families of volunteers were informed about the objectives of the study and protocols performed. As the study involved children, a signed declaration of conformity for the participation in the study was obtained from their parents and/or legal representatives.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated for this study can be found in the European Nucleotide Archive (ENA) database (https://www.ebi.ac.uk/ena/browser/home) with project ID PRJEB55393 and sample IDs SAMEA110648965-SAMEA110648977.